Tumor Targeted Lymphocytes Summit 2018
In-Person Event
Dec 11 - 13, 2018
Boston, Massachusetts, USA
OVERVIEW
Tumor Targeted Lymphocytes Summit is organized by Hanson Wade and will be held from Dec 11 - 13, 2018 at The Colonnade Boston Hotel, Boston, Massachusetts, United States of America.
Conference Description:
The Tumor Targeted Lymphocyte Summit is the first, dedicated meeting that unites the expert community working in TIL and CTL therapies to network, learn and determine strategies to enhance the efficacy of this adoptive cell therapy in solid tumors.
As CAR-T fails in the fight to deliver efficacy in solid tumors, the field is desperately exploring alternative adoptive cell therapies which are strong enough to rise to the challenge. TILs and CTLs have successfully been utilized in melanoma and now with patient demand growing, TIL-based therapies are fast becoming a more attractive approach to solid tumors.
Learn from the leading drug developers, clinicians and academic experts to improve your understanding of:
• The current clinical and translational landscape to improve upon your clinical pipeline design
• Methods to streamline the manufacture of TIL and CTL therapies to reduce cost and time expenditure
• Novel biomarkers to help select a specific, tumor-reactive, cell population and predict patient response
• Innovative strategies to genetically engineer TIL and CTL cells to enhance cell function
• The potential benefits and clinical outcomes of reduced IL-2 and preconditioning therapy
Speakers:
Edward Samuel , Joost Van Den Berg , Cyrille Cohen, Robert Hawkins, Geoffrey Stephens , Maria Fardis , Kumar Karyampudi , Chantale Bernatchez, Stephanie L. Goff, Marit Van Buuren, Linh Nguyen, Emese Zsiros, Gerrit Dispersyn, Peter Hoang , Michael Leek
Additional details will be posted as soon as they are available.
Conference Description:
The Tumor Targeted Lymphocyte Summit is the first, dedicated meeting that unites the expert community working in TIL and CTL therapies to network, learn and determine strategies to enhance the efficacy of this adoptive cell therapy in solid tumors.
As CAR-T fails in the fight to deliver efficacy in solid tumors, the field is desperately exploring alternative adoptive cell therapies which are strong enough to rise to the challenge. TILs and CTLs have successfully been utilized in melanoma and now with patient demand growing, TIL-based therapies are fast becoming a more attractive approach to solid tumors.
Learn from the leading drug developers, clinicians and academic experts to improve your understanding of:
• The current clinical and translational landscape to improve upon your clinical pipeline design
• Methods to streamline the manufacture of TIL and CTL therapies to reduce cost and time expenditure
• Novel biomarkers to help select a specific, tumor-reactive, cell population and predict patient response
• Innovative strategies to genetically engineer TIL and CTL cells to enhance cell function
• The potential benefits and clinical outcomes of reduced IL-2 and preconditioning therapy
Speakers:
Edward Samuel , Joost Van Den Berg , Cyrille Cohen, Robert Hawkins, Geoffrey Stephens , Maria Fardis , Kumar Karyampudi , Chantale Bernatchez, Stephanie L. Goff, Marit Van Buuren, Linh Nguyen, Emese Zsiros, Gerrit Dispersyn, Peter Hoang , Michael Leek
Additional details will be posted as soon as they are available.
KEY DATES
11 Dec, 2018
Event Start Date
13 Dec, 2018
Event End Date
SPECIALITIES
Immunology and MicrobiologyOncologySUGGESTED HOTELS
CONFERENCE VENUE
The Colonnade Boston HotelRELATED CONFERENCES & LIVE WEBINARS
Quick Links